The negative prognostic impact of PLS3 could be verified in a second publicly available AML patient cohort where high PLS3 expression was associated with a poor overall survival (p = 0.009; n = 553 patients, GEO accession number GSE37642) [9]. Here, PLS3 is linked to acute myeloid leukemia.